Compare AIZ & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AIZ | LEGN |
|---|---|---|
| Founded | 1892 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.4B | 5.9B |
| IPO Year | N/A | 2020 |
| Metric | AIZ | LEGN |
|---|---|---|
| Price | $232.39 | $22.09 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 13 |
| Target Price | ★ $249.17 | $69.67 |
| AVG Volume (30 Days) | 284.0K | ★ 2.6M |
| Earning Date | 11-04-2025 | 11-12-2025 |
| Dividend Yield | ★ 1.54% | N/A |
| EPS Growth | ★ 17.21 | N/A |
| EPS | ★ 16.41 | N/A |
| Revenue | ★ $12,568,700,000.00 | $909,045,000.00 |
| Revenue This Year | $8.50 | $68.83 |
| Revenue Next Year | $5.73 | $51.27 |
| P/E Ratio | $13.97 | ★ N/A |
| Revenue Growth | 6.92 | ★ 74.75 |
| 52 Week Low | $174.97 | $22.28 |
| 52 Week High | $232.02 | $45.30 |
| Indicator | AIZ | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 67.05 | 21.15 |
| Support Level | $219.63 | $26.43 |
| Resistance Level | $226.59 | $28.97 |
| Average True Range (ATR) | 3.72 | 1.36 |
| MACD | 0.28 | -0.45 |
| Stochastic Oscillator | 95.02 | 2.51 |
Assurant Inc is a protection company that partners with the brands to safeguard and service connected devices, homes and automobiles. It operate in North America, Latin America, Europe and Asia Pacific through two operating segments: Global Lifestyle and Global Housing. Global Lifestyle: includes mobile device solutions (including extended service contracts, insurance policies and related services), extended service contracts and related services for consumer electronics and appliances, and financial services and other insurance products. Global Housing: includes lender-placed homeowners, manufactured housing and flood insurance, as well as voluntary manufactured housing, condominium and homeowners insurance. Key revenue is generated from Global Lifestyle segment.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.